Format

Send to

Choose Destination
See comment in PubMed Commons below
Br J Haematol. 2012 Jul;158(2):155-64. doi: 10.1111/j.1365-2141.2012.09151.x. Epub 2012 May 10.

How I manage priapism in chronic myeloid leukaemia patients.

Author information

1
Bone Marrow Transplant Unit, Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, Glasgow, UK.

Abstract

Priapism is a rare presenting feature of chronic myeloid leukaemia (CML). It is a urological emergency requiring urgent treatment to prevent long-term complications, in particular erectile dysfunction. In males with CML, ischaemic priapism is believed to result from hyperleucocytosis and associated leucostasis or hyperviscosity, and is seen in patients presenting with a high white cell count. Increasingly, a combined modality approach is being used to treat CML patients presenting with priapism. This includes systemic therapy with chemotherapy (hydroxycarbamide or tyrosine kinase inhibitors) and therapeutic leukapheresis to reduce the white cell count as well as local intracavernous therapy. This review will examine the literature and discuss the presenting features, investigations and management of priapism in CML.

[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center